Drug    DrugBank | All Description Patterns💬 Info on mouse-over

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY On map, Yellow: Drug target genes	Disease ID
1	2'-o-(2-methoxyethyl)-d-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid	Ribose	-	-	-	[1] 131 💬
2	Alpha 1-proteinase inhibitor	Alpha-1-proteinase inhibitor	-	-	-	[1] 231 💬
3	Alpha 1-proteinase inhibitor (human)	Alpha-1-proteinase inhibitor	-	-	-	[1] 231 💬
4	Alpha-1 proteinase inhibitor (human)	-	-	-	-	[1] 231 💬
5	Alpha1-proteinase inhibitor	Alpha-1-proteinase inhibitor	-	-	-	[2] 231, 299 💬
6	Alpha1-proteinase inhibitor (human)	Alpha-1-proteinase inhibitor	-	-	-	[2] 231, 299 💬
7	Behavioral: protein and calorie controlled diet	-	-	-	-	[1] 251 💬
8	C326, il-6 inhibitory avimer protein	-	-	-	-	[1] 96 💬
9	Caveolin-1-scaffolding-protein-derived peptide (lti-03)	-	-	-	-	[1] 85 💬
10	Cgmp protein	-	-	-	-	[1] 97 💬
11	Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine	Azathioprine	[12] D00238, D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592, D02994, D03033 💬	[2] MS4A1, NR3C1 💬	[2] Hematopoietic cell lineage, Neuroactive ligand-receptor interaction	[1] 35 💬
12	Dose of 60 mg/kg alpha1-proteinase inhibitor	Alpha-1-proteinase inhibitor	-	-	-	[1] 231 💬
13	Dose of 60 mg/kg fraction iv-1 alpha1-proteinase inhibitor	Alpha-1-proteinase inhibitor	-	-	-	[1] 231 💬
14	Egg white protein	Egg	-	-	-	[1] 96 💬
15	Engineerd protein inhibitor of human neutrophil elastase	-	-	-	-	[1] 299 💬
16	Engineered protein inhibitor of human neutrophil elastase	-	-	-	-	[1] 299 💬
17	Ensure high protein	-	-	-	-	[1] 299 💬
18	Genetic: protein expression analysis	-	-	-	-	[2] 28, 60 💬
19	Glycomacropeptide-based protein substitute	-	-	-	-	[1] 240 💬
20	Hepatitis b virus surface antigen recombinant (s protein)	-	-	-	-	[1] 46 💬
21	High protein high fiber diet	-	-	-	-	[2] 93, 95 💬
22	High protein. t-diet plus range	-	-	-	-	[1]  6  💬
23	Human monoclonal antibody directed against complement 5 protein	-	-	-	-	[1] 62 💬
24	Human recombinant tissue non-specific alkaline phosphatase fusion protein	Alkaline Phosphatase	-	-	-	[1] 172 💬
25	Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy	-	-	-	-	[1]  2  💬
26	Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy chain), disulfide with human mus musculus monoclonal light chain, dimer	-	-	-	-	[1]  2  💬
27	L01xe - protein kinase inhibitors	-	-	-	-	[1] 85 💬
28	Large protein molecule	-	-	-	-	[1] 46 💬
29	Low calorie protein substitute	-	-	-	-	[1] 240 💬
30	Other: high energy / protein diet.	-	-	-	-	[1] 96 💬
31	Phenylalanine-free protein substitute in tablet form (xphe minis)	Phenylalanine	[1] D00021 💬	-	-	[1] 240 💬
32	Phenylalanine-free protein substitute tablets	Phenylalanine	[1] D00021 💬	-	-	[1] 240 💬
33	Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) conjugated to crm197 carrier protein and adsorbed on aluminium phosphate	Aluminium	-	-	-	[1] 46 💬
34	Procedure: whole body protein turnover	-	-	-	-	[4] 19, 46, 96, 299 💬
35	Procedure: whole body protein turnover study	-	-	-	-	[1] 299 💬
36	Protein	-	-	-	-	[2] 46, 67 💬
37	Protein intake	-	-	-	-	[1] 240 💬
38	Protein-carbohydrate supplementation	-	-	-	-	[1] 113 💬
39	Prtx-100 (staphylococcal protein a)	Bevifimod	-	-	-	[1] 63 💬
40	Recombinant coagulation fviii fc – von willebrand factor – xten fusion protein	Von Willebrand Factor Human	-	-	-	[1] 288 💬
41	Recombinant coagulation fviii fc – vonwillebrand factor – xten fusion protein	-	-	-	-	[1] 288 💬
42	Recombinant factor fc fusion protein	-	-	-	-	[2] 46, 49 💬
43	Recombinant human coagulation factor viii fc - von willebrand factor - xten fusion protein	Antihemophilic factor human	-	-	-	[1] 288 💬
44	Recombinant tnf-a receptor: igg fc fusion protein	-	-	-	-	[2] 46, 271 💬
45	Soy protein	-	-	-	-	[2]  6 , 96 💬
46	Soy protein isolate	-	-	-	-	[1] 227 💬
47	Staphylococcal protein a	Bevifimod	-	-	-	[1] 63 💬
48	Whey protein	-	-	-	-	[2]  6 , 96 💬
49	Whey protein&prebiotic supplement	-	-	-	-	[1] 46 💬

Back to top